Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block

John Rickard1, Mohamed Bassiouny, Edmond M Cronin

  • 1Heart and Vascular Institute Cleveland Clinic, Ohio, USA. rickarj2@ccf.org

Insights

Patients with non-left bundle branch block (LBBB) may benefit from cardiac resynchronization therapy (CRT). A wider QRS duration in these patients predicts better reverse ventricular remodeling and improved long-term outcomes with CRT.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is effective for heart failure, primarily in patients with left bundle branch block (LBBB).
  • The benefits of CRT in patients without LBBB (non-LBBB morphologies) are less understood.
  • Identifying predictors of CRT response in non-LBBB patients is crucial for optimizing treatment.

Purpose of the Study:

  • To investigate the characteristics associated with CRT response in patients with non-LBBB morphologies.
  • To determine the relationship between baseline QRS duration and long-term outcomes in this patient group.

Main Methods:

  • Retrospective analysis of 99 patients with advanced heart failure, LVEF ≤35%, and QRS duration ≥120 ms, excluding LBBB.
  • Response defined as ≥10% decrease in left ventricular end-systolic volume.
  • Multivariate models used to identify predictors of response and long-term outcomes.

Main Results:

  • 52.5% of patients with non-LBBB morphologies responded to CRT.
  • Wider QRS duration was significantly associated with CRT response (OR 1.23 per 10 ms).
  • Wider QRS duration was inversely associated with poor long-term outcomes (HR 0.79 per 10 ms).

Conclusions:

  • In patients with advanced heart failure and non-LBBB morphologies, a wider QRS duration is a key predictor of CRT effectiveness.
  • Baseline QRS duration influences reverse ventricular remodeling and long-term prognosis in non-LBBB CRT recipients.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...